Influenza :: HHS Funds Advanced Development of H5N1 Influenza Vaccines
HHS Secretary Mike Leavitt announced today that the department has awarded contracts totaling $132.5 million to three vaccine makers for the advanced development of H5N1 influenza vaccines using an immune system booster called an adjuvant. An adjuvant is a substance that may be added to a vaccine to increase the body?s immune response to the vaccine?s active ingredient, called antigen.